ClinicalTrials.gg
RecruitingNCT06440083Updated Jun 5, 2024

Pre-warning Risk Scoring System for Sudden Cardiac Death

An observational study in Sudden Cardiac Death, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 16 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-05.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100,000
Ages
16 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Death, Sudden, Cardiac with a site in China — 9 open to participants now, 10 under way, none of them phase 3. Death, Sudden, Cardiac · China.

Planned enrollment
Largest of 15
100,000 · median 1,491
Started
2023
with 1 other
Observational
15 of 19
8 open now
Registered
10th of 19
by date
Lead sponsor
2 of 19
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Among the 19 studies in Death, Sudden, Cardiac with a site in China, this one has the largest planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2023, is one of 15 observational ones, and was the 10th registered.

Death, Sudden, Cardiac

364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.

Browse Death, Sudden, Cardiac studies →

Open to participants now

9 of the 19 studies in Death, Sudden, Cardiac with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.

This study: 16 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Death, Sudden, Cardiac with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to identify potential indicators for pre-warning of sudden cardiac death (SCD), including clinical biochemistry markers, electrocardiogram, echocardiography, MRI and CT imaging values, genetic markers and so on, and further construct a series of multi-parameter assessments of SCD early screening.

Read the detailed description

In the past few decades, evidence-based drug and surgical treatment strategies have significantly improved the prevention of sudden cardiac death (SCD), however, a large number of patients with cardiovascular disease still face high risk of SCD, the prognosis of these high-risk SCD patients are still uncertain. Therefore, clinical physicians might need to move towards a multi-parameter assessment of SCD risk pre-warning. Several parameters for risk stratification of arrhythmia, including clinical biochemistry markers, electrocardiogram, echocardiography, imaging, and genetic markers, are crucial for accurate assessment of SCD risk stratification. In addition, the integration of cardiac magnetic resonance parameters and specific CT and ECG information is a future research trend for implementing risk stratification of malignant arrhythmias. In order to further explore the possibility of early warning of SCD, this study aims to include subjects with potential SCD risks, collect relevant potential SCD warning indicators, and then construct an SCD prewarning score system. Afterwards, the investigators will continuously improve the SCD warning score system based on follow-up information, and ultimately summarize an effective set of SCD warning scores and apply them to clinical practice, striving to achieve early warning of SCD and benefiting more people at risk of SCD.

03

Conditions studied

  • Sudden Cardiac Death

Keywords

  • Sudden Cardiac Death
  • Cohort study
04

Who can participate

Ages eligible
16 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants with potential high-risk of sudden cardiac death.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The subjects with the following diagnosis of one or more cardiovascular diseases:

  1. Coronary heart disease If there is a history of coronary heart disease or a new diagnosis of coronary heart disease, or with a report of coronary angiography that indicates at least one vascular stenosis>50%. Diagnosis includes chronic coronary syndrome (stable angina, ischemic cardiomyopathy, and occult coronary heart disease) and acute coronary syndrome (unstable angina, ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction).
  2. Heart failure Individuals with a history of heart failure or newly diagnosed heart failure, including heart failure with reduced (HFrEF, left ventricular ejection fraction (LVEF) ≤40%)、intermediate heart failure (HFmrEF, LVEF 41%-49%,with evidence of spontaneous or excitable increase in left ventricular filling pressure), and ejection fraction preserving heart failure (HFpEF, LVEF≥50%, there is evidence of spontaneous or excitable increase in left ventricular filling pressure).
  3. Genetically related cardiomyopathy or arrhythmia Cardiomyopathy includes hypertrophic cardiomyopathy (DCM), dilated cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), inflammatory cardiomyopathy (myocarditis, sarcoidosis, Chagas disease). Hereditary arrhythmias include long syndrome, short QT syndrome, Brugada syndrome, idiopathic ventricular fibrillation, catecholamine sensitive polymorphic ventricular tachycardia (CPVT), early repolarization syndrome, etc.
  1. Sign an form.

Exclusion criteria

Exclusion Criteria:

  1. Age\<16 years old;
  2. Refusal to the follow-up visits;
  3. Individuals with severe mental disorders who are unable to express their wishes;
  4. Other obvious physical diseases and abnormal laboratory test results;
  5. Patients deemed unsuitable for participation in this study by the supervising physician.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Sudden cardiac death

    Identify participants who die by cardiovascular diseases during follow-up period

    Time frame: Baseline and to the 1-year, 2-year, 5-year follow-up

Secondary outcomes

  1. All-causes death

    Identify participants who die during follow-up period

    Time frame: Baseline and to the 1-year, 2-year, 5-year follow-up

  2. Recurrence of cardiovascular disease

    Identify participants who with recurrence of cardiovascular disease during follow-up period

    Time frame: Baseline and to the 1-year, 2-year, 5-year follow-up

  3. Cardiac arrest

    Identify participants who suffer sudden cardiac arrest during follow-up period

    Time frame: Baseline and to the 1-year, 2-year, 5-year follow-up

  4. Major cardiovascular events

    Identify participants who suffer incident major cardiovascular events during follow-up period

    Time frame: Baseline and to the 1-year, 2-year, 5-year follow-up

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2027, 57 months after the start.

Of 70 non-industry observational studies under Death, Sudden, Cardiac, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 42. This study's planned 57 months is below that.

Counting every sponsor, half of 86 studies reached it within 63 months; a quarter within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 3, 2024
StartActual
Mar 2, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06440083
Responsible party
Jingfeng Wang (Professor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Jun 3, 2024
Start date
Mar 2, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 5, 2024

Study contacts

Yuling Zhang, M.D.,Ph.D.
Contact
zhyul@mail.sysu.edu.cn
+862081332360
Maohuan Lin, M.D.,Ph.D.
Contact
lmhuan@mail.sysu.edu.cn
+862081332360
Jingfeng Wang, M.D.,Ph.D.
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion